It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tet-enzyme-mediated 5-hydroxymethylation of cytosines in DNA plays a crucial role in mouse embryonic stem cells (ESCs). In RNA also, 5-hydroxymethylcytosine (5hmC) has recently been evidenced, but its physiological roles are still largely unknown. Here we show the contribution and function of this mark in mouse ESCs and differentiating embryoid bodies. Transcriptome-wide mapping in ESCs reveals hundreds of messenger RNAs marked by 5hmC at sites characterized by a defined unique consensus sequence and particular features. During differentiation a large number of transcripts, including many encoding key pluripotency-related factors (such as Eed and Jarid2), show decreased cytosine hydroxymethylation. Using Tet-knockout ESCs, we find Tet enzymes to be partly responsible for deposition of 5hmC in mRNA. A transcriptome-wide search further reveals mRNA targets to which Tet1 and Tet2 bind, at sites showing a topology similar to that of 5hmC sites. Tet-mediated RNA hydroxymethylation is found to reduce the stability of crucial pluripotency-promoting transcripts. We propose that RNA cytosine 5-hydroxymethylation by Tets is a mark of transcriptome flexibility, inextricably linked to the balance between pluripotency and lineage commitment.
TET mediated RNA-hydroxymethylation (5hmC) has been detected in mammals, but its physiological role remains unclear. Here the authors map 5hmC during embryonic stem cell (ESC) differentiation and find that Tet-mediated RNA hydroxymethylation reduces the stability of crucial pluripotency related transcripts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Université Libre de Bruxelles (ULB), Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB Cancer Research Center (U-CRC), Welbio Investigator, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
2 CiMUS, Universidade de Santiago de Compostela–Health Research Institute (IDIS), Santiago de Compostela, Spain (GRID:grid.507073.6)
3 University of Chicago, Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, and Howard Hughes Medical Institute, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822)
4 Wuhan University, Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), Department of Chemistry, Wuhan, People’s Republic of China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)
5 The University of Sydney, Epigenetics and RNA Biology Program Centenary Institute, Camperdown, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
6 Ghent University, Department of Mathematical Modeling, Statistics and Bioinformatics, Faculty of Bioscience Engineering, Lab of Bioinformatics and Computational Genomics, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
7 Columbia University Irving Medical Center (CUIMC), Department of Medicine, Columbia Center for Human Development (CCHD), New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
8 Université Libre de Bruxelles (ULB), Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB Cancer Research Center (U-CRC), Welbio Investigator, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); WELBIO (Walloon Excellence in Lifesciences & Biotechnology), Brussels, Belgium (GRID:grid.4989.c)